{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:14:15Z","timestamp":1793830455573,"version":"4.6.1"},"reference-count":45,"publisher":"European Respiratory Society (ERS)","issue":"154","license":[{"start":{"date-parts":[[2019,11,6]],"date-time":"2019-11-06T00:00:00Z","timestamp":1572998400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir Rev"],"accepted":{"date-parts":[[2019,6,8]]},"published-print":{"date-parts":[[2019,12,31]]},"abstract":"<jats:p>Immunotherapy has become a standard of care in oncology, following the recent approvals of cytotoxic T-lymphocyte-associated protein-4 and programmed cell death-1 inhibitors in lung cancer, melanoma, renal cell carcinoma, Hodgkin's lymphoma, bladder, head and neck cancers. Besides their efficacy, these agents also generate specific immune-related adverse events. Due to the increasing prescription of immune-checkpoint inhibitors, the incidence of immune toxicity will continue to rise. The awareness of immune-related adverse events is key to ensuring both diagnosis and management of the possible serious adverse events. Although severe immune-related adverse events remain rare, they can lead to discontinued treatment or to death if they are not forecasted and managed properly. Even if lung toxicity is not the most frequent adverse event, it remains critical as it can be life-threatening. Herein, the main aspects of pulmonary toxicity are reviewed and guidelines are also proposed in order to manage the possible side-effects.<\/jats:p>","DOI":"10.1183\/16000617.0012-2019","type":"journal-article","created":{"date-parts":[[2019,11,6]],"date-time":"2019-11-06T16:49:17Z","timestamp":1573058957000},"page":"190012","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":90,"title":["Management of pulmonary toxicity associated with immune checkpoint inhibitors"],"prefix":"10.1183","volume":"28","author":[{"given":"Myriam","family":"Delaunay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gr\u00e9goire","family":"Pr\u00e9vot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samia","family":"Collot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Guilleminault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Didier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Mazi\u00e8res","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2019,11,6]]},"reference":[{"key":"2024102403415624000_28.154.190012.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00561-4"},{"key":"2024102403415624000_28.154.190012.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1602252"},{"key":"2024102403415624000_28.154.190012.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411087"},{"key":"2024102403415624000_28.154.190012.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.11.016"},{"key":"2024102403415624000_28.154.190012.5","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1001\/jamaoncol.2016.2453","article-title":"Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis","volume":"2","author":"Nishino","year":"2016","journal-title":"JAMA Oncol"},{"key":"2024102403415624000_28.154.190012.6","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00050-2017"},{"key":"2024102403415624000_28.154.190012.7","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","article-title":"Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy","volume":"35","author":"Naidoo","year":"2017","journal-title":"J Clin Oncol"},{"key":"2024102403415624000_28.154.190012.8","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1320"},{"key":"2024102403415624000_28.154.190012.9","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30498-3"},{"key":"2024102403415624000_28.154.190012.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709937"},{"key":"2024102403415624000_28.154.190012.11","doi-asserted-by":"publisher","DOI":"10.1378\/chest.126.6.1750"},{"key":"2024102403415624000_28.154.190012.12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2017.06.008","article-title":"A pilot trial of nivolumab treatment for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia","volume":"111","author":"Fujimoto","year":"2017","journal-title":"Lung Cancer"},{"key":"2024102403415624000_28.154.190012.13","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.jcma.2016.01.008","article-title":"Radiation recall pneumonitis induced by epidermal growth factor receptor-tyrosine kinase inhibitor in patients with advanced nonsmall-cell lung cancer","volume":"79","author":"Chiang","year":"2016","journal-title":"J Chin Med Assoc"},{"key":"2024102403415624000_28.154.190012.14","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.chest.2017.04.177","article-title":"Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: a systematic review and meta-analysis of trials","volume":"152","author":"Khunger","year":"2017","journal-title":"Chest"},{"key":"2024102403415624000_28.154.190012.15","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/CCO.0000000000000291","article-title":"Immune-mediated respiratory adverse events of checkpoint inhibitors","volume":"28","author":"Tabchi","year":"2016","journal-title":"Curr Opin Oncol"},{"key":"2024102403415624000_28.154.190012.16","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","article-title":"Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders","volume":"2","author":"Johnson","year":"2016","journal-title":"JAMA Oncol"},{"key":"2024102403415624000_28.154.190012.17","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab","volume":"28","author":"Menzies","year":"2017","journal-title":"Ann Oncol"},{"key":"2024102403415624000_28.154.190012.18","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1200\/JCO.2017.77.0305","article-title":"Safety of programmed death-1 pathway inhibitors among patients with non-small-cell lung cancer and preexisting autoimmune disorders","volume":"36","author":"Leonardi","year":"2018","journal-title":"J Clin Oncol"},{"key":"2024102403415624000_28.154.190012.19","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0123"},{"key":"2024102403415624000_28.154.190012.20","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201308-1483ST"},{"key":"2024102403415624000_28.154.190012.21","doi-asserted-by":"publisher","DOI":"10.1378\/chest.12-1467"},{"key":"2024102403415624000_28.154.190012.22","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e318206a221"},{"key":"2024102403415624000_28.154.190012.23","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1183\/09031936.93.06040477","article-title":"Density of phenotypic markers on BAL T-lymphocytes in hypersensitivity pneumonitis, pulmonary sarcoidosis and bronchiolitis obliterans with organizing pneumonia","volume":"6","author":"Satake","year":"1993","journal-title":"Eur Respir J"},{"issue":"Suppl. 4","key":"2024102403415624000_28.154.190012.24","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"2024102403415624000_28.154.190012.25","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"2024102403415624000_28.154.190012.26","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) toxicity management working group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"key":"2024102403415624000_28.154.190012.27","first-page":"951","article-title":"[Drug-induced interstitial lung diseases]","volume":"64","author":"Bonniaud","year":"2014","journal-title":"Rev Prat"},{"key":"2024102403415624000_28.154.190012.28","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0352"},{"key":"2024102403415624000_28.154.190012.29","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1159\/000494841","article-title":"Recurrent episodes of nivolumab-induced pneumonitis after nivolumab discontinuation and the time course of carcinoembryonic antigen levels: a case of a 58-year-old woman with non-small cell lung cancer","volume":"63","author":"de Jong","year":"2018","journal-title":"Chemotherapy"},{"key":"2024102403415624000_28.154.190012.30","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.06.00013505"},{"key":"2024102403415624000_28.154.190012.31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1703047"},{"key":"2024102403415624000_28.154.190012.32","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0755"},{"key":"2024102403415624000_28.154.190012.33","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.3298"},{"key":"2024102403415624000_28.154.190012.34","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.rmr.2018.08.003","article-title":"[Sarcoid-like granulomatosis in cancer patients treated with immune checkpoints inhibitors]","volume":"35","author":"Faviez","year":"2018","journal-title":"Rev Mal Respir"},{"key":"2024102403415624000_28.154.190012.35","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0715"},{"key":"2024102403415624000_28.154.190012.36","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/annonc\/mdw655","article-title":"Pembrolizumab-induced bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm","volume":"28","author":"Haddox","year":"2017","journal-title":"Ann Oncol"},{"key":"2024102403415624000_28.154.190012.37","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s40425-017-0258-x","article-title":"Progressive hypoventilation due to mixed CD8(+) and CD4(+) lymphocytic polymyositis following tremelimumab\u2013durvalumab treatment","volume":"5","author":"John","year":"2017","journal-title":"J Immunother Cancer"},{"key":"2024102403415624000_28.154.190012.38","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1016\/j.jtho.2016.10.008","article-title":"Anti-PD-1 antibody treatment and the development of acute pulmonary tuberculosis","volume":"11","author":"Reungwetwattana","year":"2016","journal-title":"J Thorac Oncol"},{"key":"2024102403415624000_28.154.190012.39","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.cmi.2017.12.003","article-title":"Infectious complications associated with the use of immune checkpoint inhibitors in oncology: reactivation of tuberculosis after anti PD-1 treatment","volume":"24","author":"Picchi","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"2024102403415624000_28.154.190012.40","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.ejca.2016.12.027","article-title":"Allergic broncho-pulmonary aspergillosis following treatment with an anti-programmed cell death protein 1 monoclonal antibody therapy","volume":"75","author":"Pradere","year":"2017","journal-title":"Eur J Cancer"},{"key":"2024102403415624000_28.154.190012.41","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/annonc\/mdw640","article-title":"Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer","volume":"28","author":"Osorio","year":"2017","journal-title":"Ann Oncol"},{"issue":"Suppl. 5","key":"2024102403415624000_28.154.190012.42","first-page":"mdx380.017","article-title":"1314PAssociation between immune-related adverse events (irAEs) and atezolizumab efficacy in advanced NSCLC: analyses from the phase III study OAK","volume":"28","author":"von Pawel","year":"2017","journal-title":"Ann Oncol"},{"key":"2024102403415624000_28.154.190012.43","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.lungcan.2017.11.019","article-title":"Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab","volume":"115","author":"Sato","year":"2018","journal-title":"Lung Cancer"},{"key":"2024102403415624000_28.154.190012.44","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4321"},{"key":"2024102403415624000_28.154.190012.45","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv623"}],"container-title":["European Respiratory Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/16000617.0012-2019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T05:01:16Z","timestamp":1740373276000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/16000617.0012-2019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,6]]},"references-count":45,"journal-issue":{"issue":"154","published-online":{"date-parts":[[2019,11,6]]},"published-print":{"date-parts":[[2019,12,31]]}},"alternative-id":["10.1183\/16000617.0012-2019"],"URL":"https:\/\/doi.org\/10.1183\/16000617.0012-2019","relation":{},"ISSN":["0905-9180","1600-0617"],"issn-type":[{"value":"0905-9180","type":"print"},{"value":"1600-0617","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,6]]}}}